Keyphrases
Respiratory Syncytial Virus
100%
Respiratory Syncytial Virus Infection
56%
Respiratory Syncytial Virus Bronchiolitis
36%
Lower Respiratory Tract Infection
28%
Wheezing
21%
Disease Severity
14%
Bronchiolitis
12%
Preterm Infants
12%
Netherlands
10%
Virus Diseases
9%
Hospitalization
9%
Down Syndrome
9%
Palivizumab
9%
Children with Down Syndrome
9%
Respiratory Infection
9%
Recurrent Wheezing
8%
Interleukin-10
8%
Viral Infection
7%
Leukocytes
7%
Recurrent Wheeze
7%
Immune Response
7%
Single nucleotide Polymorphism
7%
Asthma
6%
Risk Factors
6%
Toll-like
6%
Virus
6%
Gestational Age
6%
First Year of Life
6%
Confidence Interval
6%
Young children
6%
Inhibitory Receptors
6%
Respiratory Syncytial Virus Hospitalization
5%
Healthy children
5%
Viral
5%
Mechanical Ventilation
5%
Monoclonal Antibody
5%
Randomized Placebo-controlled Trial
5%
Infections in children
5%
Innate Immune Response
5%
Respiratory Syncytial Virus Vaccines
5%
Strength of Evidence
5%
Polymorphism
5%
Viral Respiratory Infections
5%
Birth Cohort Study
5%
Bacterial Infection
5%
Neonate
5%
Disease Burden
5%
Immunology and Microbiology
Human Respiratory Syncytial Virus
94%
Respiratory Syncytial Virus Infection
43%
Bronchiolitis
35%
Lower Respiratory Tract
22%
Asthma
10%
Respiratory Syncytial Virus
9%
Interleukin 10
8%
Immunity
8%
Immune Response
8%
Infectious Agent
8%
Innate Immune System
7%
Palivizumab
7%
Viral Disease
7%
Human Immunodeficiency Virus
7%
Leukocyte
7%
Intravenous Immunoglobulin
5%
Infancy
5%
Single Nucleotide Polymorphism
5%
Cytokine
5%
Neutrophil Granulocyte
5%
Medicine and Dentistry
Human Respiratory Syncytial Virus
54%
Wheeze
27%
Respiratory Syncytial Virus Infection
25%
Bronchiolitis
20%
Lower Respiratory Tract Infection
16%
Respiratory Tract Infection
11%
Disease
10%
Respiratory Syncytial Virus
9%
Infection
8%
Toddlers
7%
Asthma
6%
Virus Infection
6%
Lung
6%
Respiratory Disease
6%
Cohort Analysis
5%
Placebo
5%
Palivizumab
5%
Human Immunodeficiency Virus
5%
Amnion Fluid
5%
